[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Minerva Neurosciences (NERV) reported a routine equity compensation grant to a non-employee director. On 11/14/2025, the director received a stock option to purchase 9,500 shares of Minerva common stock at an exercise price of $4.11 per share. The option vests in equal quarterly installments over three years, with the first installment vesting on February 14, 2026, as long as the individual continues to serve as a non-employee director on each vesting date. The option expires on November 13, 2035, giving a long-term incentive aligned with the company’s share performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaul Inderjit

(Last) (First) (Middle)

C/O MINERVA NEUROSCIENCES, INC.

1500 DISTRICT AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.11	11/14/2025		A		9,500		(1)	11/13/2035	Common Stock	9,500	$0	9,500	D

Explanation of Responses:

1. The shares subject to this option vest in equal quarterly installments over three years with the first installment vesting on February 14, 2026, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

	/s/ Frederick Ahlholm, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Minerva Neurosciences (NERV) disclose in this Form 4 filing?

Minerva Neurosciences disclosed that a non-employee director received a stock option grant to purchase 9,500 shares of its common stock, reflecting routine director equity compensation.

How many Minerva Neurosciences (NERV) shares are covered by the new option grant?

The reported stock option covers 9,500 shares of Minerva Neurosciences common stock, as shown in Table II of the Form 4.

What is the exercise price of the Minerva Neurosciences (NERV) director stock option?

The stock option granted to the non-employee director has an exercise price of $4.11 per share for Minerva Neurosciences common stock.

When do the Minerva Neurosciences (NERV) director options start vesting and over what period?

The options begin vesting on February 14, 2026 and vest in equal quarterly installments over three years, subject to the director’s continued service on each vesting date.

When do the newly granted Minerva Neurosciences (NERV) stock options expire?

The director’s stock options reported in this Form 4 expire on November 13, 2035, providing a long-term window to exercise the award.

Who is the reporting person in this Minerva Neurosciences (NERV) Form 4 and what is their role?

The reporting person is identified as a Director of Minerva Neurosciences, serving as a non-employee director eligible for equity-based compensation.